Clinical Trials
14
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (11 trials with phase data)• Click on a phase to view related trials
rFVIII-Fc (Produced by AryoGen Pharmed Co.) Pharmacokinetic Study
- Conditions
- Severe Hemophilia A
- Interventions
- Drug: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
- First Posted Date
- 2023-11-18
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 50
- Registration Number
- NCT06137092
- Locations
- 🇮🇷
Seyed-Al-Shohada Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Sarvar Clinic, Mashhad, Iran, Islamic Republic of
🇮🇷Dastqeib Hospital, Shiraz, Iran, Islamic Republic of
AryoTrust® (Trastuzumab) Safety Study
- First Posted Date
- 2023-09-01
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 597
- Registration Number
- NCT06021379
- Locations
- 🇮🇷
5th Azar Hospital, Gorgān, Iran, Islamic Republic of
🇮🇷Milad Hospital, Isfahan, Iran, Islamic Republic of
🇮🇷Mahdieh Clinic, Kermanshah, Iran, Islamic Republic of
Study on the Dose-response Relationship of Pharmacodynamic Parameters in Patients With Hemophilia With Inhibitors
- Conditions
- Hemophilia A With InhibitorHemophilia B With Inhibitor
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2022-09-10
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 14
- Registration Number
- NCT04789954
- Locations
- 🇮🇷
Comprehensive Hemophilia Care Center, Teheran, Iran, Islamic Republic of
Assessment of Treatment Safety and Quality of Life in Patients Receiving Etanercept Biosimilar for Autoimmune Arthritis
- Conditions
- Psoriatic ArthritisAnkylosing SpondylitisRheumatoid Arthritis
- Interventions
- First Posted Date
- 2020-10-09
- Last Posted Date
- 2020-10-19
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 583
- Registration Number
- NCT04582084
- Locations
- 🇮🇷
Connective Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, East Azerbaijan, Iran, Islamic Republic of
🇮🇷Hafez Hospital, Shiraz, Fars, Iran, Islamic Republic of
🇮🇷Razi Hospital, Rasht, Guilan, Iran, Islamic Republic of
Clinical Trial Comparing a Biosimilar Eptacog Alfa With Novoseven, in Patients With Hemophilia With Inhibitors
- Conditions
- Hemophilia A or B With Inhibitor
- First Posted Date
- 2019-05-02
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- AryoGen Pharmed Co.
- Target Recruit Count
- 48
- Registration Number
- NCT03935334
- Locations
- 🇮🇷
Hemophilia Center - Hematology & Oncology Dept. Shiraz University of Medical Science, Shiraz, Iran, Islamic Republic of
🇮🇷Comprehensive Hemophilia Care Center, Teheran, Iran, Islamic Republic of
🇮🇷Ali Asghar Hospital, Zahedan, Iran, Islamic Republic of
- Prev
- 1
- 2
- 3
- Next